Related Experiment Video
Updated: May 15, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Aliskiren induced remarkable hypertriglyceridemia
Kengo Azushima1, Kouichi Tamura, Hiromichi Wakui
1Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan. fqqxj908@ybb.ne.jp
We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.
We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Potassium-Sparing Diuretics